SCHEMBL6508702

SCHEMBL6508702

Cc1[nH]nc2c1c(=O)n(CCCNC(=O)CCCN)c1ccccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 5/20 0.56
AURKA O14965 1/20 0.51
KDR P35968 1/20 0.51
AURKB Q96GD4 1/20 0.51
KCNH2 Q12809 1/20 0.47
PLK1 P53350 1/20 0.46
RXFP1 Q9HBX9 1/20 0.44
TP53 P04637 2/20 0.42
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
MAPT P10636 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6517711 0.96 CHEK1 (0.55) CHEK1AURKAKDRAURKBKCNH2
SCHEMBL6508848 0.91 AURKA (0.54) CHEK1AURKAKDRAURKBKCNH2
SCHEMBL6522416 0.89 MAPT (0.49) CHEK1AURKAKDRAURKBTP53
SCHEMBL6512770 0.88 AURKA (0.50) CHEK1AURKAKDRAURKBTP53
SCHEMBL6510076 0.86 AURKA (0.57) CHEK1AURKAKDRAURKBKCNH2
SCHEMBL6514411 0.86 PLK1 (0.51) CHEK1AURKAKDRAURKBPLK1
SCHEMBL6507581 0.86 CHEK1 (0.72) CHEK1AURKAKDRAURKBKCNH2
SCHEMBL6518613 0.86 AURKA (0.52) CHEK1AURKAKDRAURKBKCNH2
SCHEMBL6515626 0.84 PLK1 (0.49) CHEK1AURKAKDRAURKBPLK1
SCHEMBL6515406 0.82 KDR (0.52) CHEK1AURKAKDRAURKBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 CHEK1 3/4885AURKA 78/4885KDR 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.